Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

NCT06913023 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing whether semaglutide can help prevent diabetes in people who have received a kidney transplant.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 74 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-01 · est. completion 2027-11

Where 2 sites · Canada

What this study is testing ClinicalTrials.gov NCT06913023 ↗

Description as written by the study sponsor.

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).

Treatments tested

Semaglutide 3 MG [Rybelsus] Drug

Semaglutide 3mg for 4 weeks.
Semaglutide 7 MG [Rybelsus] Drug

Semaglutide 7mg for 4 weeks.
Semaglutide 14 MG [Rybelsus] Drug

Semaglutide 14mg for 16 weeks.
Placebo Oral Tablet Drug

Placebo tablet

Main thing measured	2-hour OGTT
Sponsor	University Health Network, Toronto
Conditions studied	Kidney Transplant Recipient
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06913023 ↗